For
patients who have had an acute coronary syndrome (ACS) and who are taking dual
antiplatelet therapy with low-dose aspirin and clopidogrel 75 mg daily, one
should add rivaroxaban 2.5 mg twice daily if there are no risk factors for
bleeding present.
The
duration of treatment with rivaroxaban is approximately one year, as studied in
the randomized trial. Patients may reasonably choose to not take rivaroxaban if
they are particularly concerned about the bleeding risk. This recommendation
does not apply to patients taking either prasugrel or ticagrelor.
(ATLAS 2
ACS-TIMI 51 trial)
